Panacea Biotec has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026. The filing confirms the company’s continued adherence to sustainability disclosure norms under SEBI regulations.

The report was filed pursuant to Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. While Panacea Biotec does not fall within the top 1,000 listed entities based on market capitalization as of December 31, 2025, it is voluntarily continuing to comply with relevant BRSR provisions applicable in previous years.

General Disclosures

The report covers standalone operations for the current financial year, April 1, 2025 to March 31, 2026. Key corporate details include:

Ankit Jain, General Manager - Legal & Company Secretary, signed the filing on September 7, 2026. The complete BRSR forms part of the Annual Report for FY26 and is accessible via the company’s website.

Business Activities

Panacea Biotec operates exclusively in the pharmaceutical sector. The manufacturing of pharmaceuticals, medicinal, chemical, and botanical products accounts for 100% of the entity’s turnover. This concentration underscores the company’s focused operational strategy within the healthcare domain.

The company disclosed that it has not instituted any process to monitor or verify whether suppliers or distributors participate in its business responsibility initiatives. No assurance provider was engaged for this reporting cycle.

Panacea Biotec will hold its 42nd Annual General Meeting on September 29, 2026, at 11:30 am via video conferencing. The register of members will close from September 25 to September 29, 2026.

The meeting agenda includes the adoption of audited standalone and consolidated financial statements for FY26. Shareholders will also vote on the re-appointment of directors Ankesh Jain and Harshet Jain, who retire by rotation.

Board Appointments

A special resolution seeks approval for the appointment of Rajinder Singh Manku as an independent director. His term begins July 1, 2026, for five consecutive years. The Nomination and Remuneration Committee recommended his candidacy based on his experience in project planning and finance.

Cost Auditor Remuneration

The board proposes ratifying the remuneration for cost auditors M/s Jain Sharma & Associates. The fee is set at ₹1,25,000 for the financial year 2026-27. This amount includes out-of-pocket expenses but excludes outstation travel costs and applicable taxes.

Voting and Participation

Remote e-voting opens on September 26, 2026, at 9:00 am and closes on September 28, 2026, at 5:00 pm. The cut-off date for voting eligibility is September 22, 2026. Members can attend the meeting through the NSDL e-voting system. Physical copies of the annual report are available only upon request.